Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BAYRY Bayer Aktiengesellschaft	$7.89 +2.9%	$7.02	$4.79 ▼ $8.58	$31.01B	0.85	787,890 shs	171,992 shs
BMY Bristol Myers Squibb	$46.76 +0.2%	$47.96	$39.35 ▼ $63.33	$95.21B	0.38	12.87 million shs	5.22 million shs
CSLLY CSL	$77.22 -2.8%	$78.71	$70.22 ▼ $109.00	$74.78B	0.8	91,615 shs	10,481 shs
GSK GSK	$38.74 +0.5%	$38.81	$31.72 ▼ $44.67	$79.37B	0.52	4.91 million shs	1.29 million shs

20 High-Yield Dividend Stocks that Could Ruin Your Retirement

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BAYRY Bayer Aktiengesellschaft	0.00%	-1.41%	+8.18%	+24.82%	+10.36%
BMY Bristol Myers Squibb	-0.10%	-0.30%	-0.35%	-22.32%	+9.84%
CSLLY CSL	+1.94%	+0.65%	-1.70%	+0.58%	-18.44%
GSK GSK	+0.85%	-0.16%	-2.15%	-0.38%	-0.71%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BAYRY Bayer Aktiengesellschaft	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BMY Bristol Myers Squibb	4.903 of 5 stars	3.2	3.0	4.2	4.0	3.4	3.3	1.3
CSLLY CSL	0.8376 of 5 stars	0.0	3.0	1.7	0.0	1.0	0.0	1.3
GSK GSK	2.024 of 5 stars	1.1	4.0	2.5	0.0	1.9	0.0	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BAYRY Bayer Aktiengesellschaft	3.25	Buy	N/A	N/A
BMY Bristol Myers Squibb	2.32	Hold	$58.00	24.05% Upside
CSLLY CSL	4.00	Strong Buy	N/A	N/A
GSK GSK	2.10	Hold	$37.38	-3.51% Downside

Current Analyst Ratings Breakdown

Latest BAYRY, BMY, GSK, and CSLLY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/11/2025	BAYRY Bayer Aktiengesellschaft	Hsbc Global Res Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
6/11/2025	BAYRY Bayer Aktiengesellschaft	Kepler Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy
6/5/2025	BAYRY Bayer Aktiengesellschaft	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
6/3/2025	GSK GSK	Berenberg Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
4/28/2025	BAYRY Bayer Aktiengesellschaft	Hsbc Global Res Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
4/28/2025	GSK GSK	Hsbc Global Res Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell
4/25/2025	BMY Bristol Myers Squibb	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
4/25/2025	BMY Bristol Myers Squibb	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
4/23/2025	BMY Bristol Myers Squibb	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$70.00 ➝ $68.00
4/22/2025	BMY Bristol Myers Squibb	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$55.00 ➝ $55.00
4/22/2025	BMY Bristol Myers Squibb	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$65.00

(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BAYRY Bayer Aktiengesellschaft	$50.44B	0.61	$3.91 per share	2.02	$8.82 per share	0.89
BMY Bristol Myers Squibb	$48.30B	1.97	$5.90 per share	7.93	$8.08 per share	5.79
CSLLY CSL	$14.80B	5.05	$3.94 per share	19.58	$20.07 per share	3.85
GSK GSK	$40.10B	1.98	$5.65 per share	6.86	$8.07 per share	4.80

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BAYRY Bayer Aktiengesellschaft	-$2.76B	-$0.92	N/A	6.92	N/A	-7.26%	13.94%	4.09%	8/5/2025 (Estimated)
BMY Bristol Myers Squibb	-$8.95B	$2.67	17.52	7.68	1.38	11.38%	87.62%	15.98%	7/31/2025 (Estimated)
CSLLY CSL	$2.64B	N/A	0.00	18.88	1.90	N/A	N/A	N/A	8/19/2025 (Estimated)
GSK GSK	$3.29B	$1.94	19.98	8.33	1.34	9.89%	48.82%	11.15%	7/30/2025 (Estimated)

Latest BAYRY, BMY, GSK, and CSLLY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	BAYRY Bayer Aktiengesellschaft	$0.63	$0.65	+$0.02	$0.35	$13.39 billion	$15.27 billion
4/30/2025	Q1 2025	GSK GSK	$1.08	$1.13	+$0.05	$1.00	$7.52 billion	$10.06 billion
4/24/2025	Q1 2025	BMY Bristol Myers Squibb	$1.50	$1.80	+$0.30	$1.21	$10.77 billion	$11.20 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BAYRY Bayer Aktiengesellschaft	$0.02	0.25%	N/A	N/A	N/A
BMY Bristol Myers Squibb	$2.48	5.30%	N/A	92.88%	17 Years
CSLLY CSL	$1.20	1.55%	N/A	N/A	N/A
GSK GSK	$1.69	4.36%	N/A	87.11%	N/A

Latest BAYRY, BMY, GSK, and CSLLY Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/17/2025	BMY Bristol Myers Squibb	quarterly	$0.62	5.25%	7/3/2025	7/3/2025	8/1/2025
5/2/2025	GSK GSK	quarterly	$0.4216	4.1%	5/16/2025	5/16/2025	7/10/2025
4/22/2025	BAYRY Bayer Aktiengesellschaft		$0.0224	0.38%	4/29/2025	4/30/2025	5/12/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BAYRY Bayer Aktiengesellschaft	1.07	1.25	0.79
BMY Bristol Myers Squibb	2.65	1.28	1.17
CSLLY CSL	0.45	1.86	0.85
GSK GSK	1.21	0.87	0.58

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BAYRY Bayer Aktiengesellschaft	N/A
BMY Bristol Myers Squibb	76.41%
CSLLY CSL	0.03%
GSK GSK	15.74%

Insider Ownership

Company	Insider Ownership
BAYRY Bayer Aktiengesellschaft	N/A
BMY Bristol Myers Squibb	0.09%
CSLLY CSL	N/A
GSK GSK	10.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BAYRY Bayer Aktiengesellschaft	92,815	3.93 billion	N/A	Not Optionable
BMY Bristol Myers Squibb	34,100	2.04 billion	2.03 billion	Optionable
CSLLY CSL	32,698	968.42 million	N/A	Not Optionable
GSK GSK	68,629	2.05 billion	1.84 billion	Optionable

BAYRY, BMY, GSK, and CSLLY Headlines

Recent News About These Companies

US Senator investigates GSK for pulling children's asthma inhaler

3 hours ago | reuters.com

Save The Children, GSK Seek Grassroots Innovations To Boost Vaccination

June 27 at 3:33 AM | leadership.ngL

Envestnet Portfolio Solutions Inc. Sells 28,957 Shares of GSK PLC Sponsored ADR (NYSE:GSK)

June 27 at 3:27 AM | marketbeat.com

GSK, Gilead, Novo Nordisk join other Big Pharmas in honoring 2025 LGBTQ+ Pride month

June 26 at 5:28 PM | fiercepharma.comF

GSK’s Belimumab Study: A Promising Update for SLE Treatment

June 26 at 12:40 PM | tipranks.com

GSK Advances in Atopic Dermatitis Treatment with Long-Term Study

June 26 at 12:40 PM | tipranks.com

Bharat Biotech, GSK to cut malaria vaccine price

June 26 at 12:27 PM | dailypioneer.comD

GSK to slash cost of malaria jab by more than half

June 26 at 12:27 PM | telegraph.co.uk

Bharat Biotech, GSK to slash malaria vax prices to less than $5 per dose by 2028

June 26 at 7:26 AM | msn.com

Aurora Private Wealth Inc. Invests $692,000 in GSK PLC Sponsored ADR (NYSE:GSK)

June 26 at 5:29 AM | marketbeat.com

Bharat Biotech, GSK to halve malaria vaccine price to less than $5 per dose

June 26 at 2:26 AM | moneycontrol.com

Bharat Biotech, GSK to slash malaria vaccine price

June 26 at 2:26 AM | economictimes.indiatimes.com

Bharat Biotech And GSK Cut The Price Of The World's First Malaria Vaccine To Under $5 By 2028

June 26 at 2:26 AM | republicworld.comR

GSK, Bharat Biotech to slash the price of first malaria vaccine to less than $5 per dose by 2028

June 26 at 2:26 AM | fiercepharma.comF

GSK, Bharat Biotech to slash malaria vaccine prices to under $5 per dose by 2028

June 26 at 2:26 AM | msn.com

Bharat Biotech and GSK slash price of world’s first malaria vaccine for children in endemic nations

June 25 at 10:27 AM | theweek.inT

Ruby Paralyzed, Aria Killed—Both Were Vaccinated; GSK Speaks

June 25 at 10:27 AM | msn.com

Bharat Biotech and GSK cut price of world's first malaria vaccine to under $5

June 25 at 10:27 AM | msn.com

Bharat Biotech, GSK to cut malaria vaccine price by half for children

June 25 at 10:27 AM | business-standard.comB

Bharat Biotech, GSK to halve price of malaria vaccine by 2028

June 25 at 5:27 AM | msn.com

Bharat Biotech & GSK reduce price of world’s first malaria vaccine RTS.S for kids in endemic countries to less than $5

June 25 at 5:27 AM | pharmabiz.comP

New MarketBeat Followers Over Time

Media Sentiment Over Time

BAYRY, BMY, GSK, and CSLLY Company Descriptions

Bayer Aktiengesellschaft OTCMKTS:BAYRY

$7.89 +0.22 (+2.87%)

As of 11:40 AM Eastern

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines for self-medication and self-care; and solutions for nutritional supplements, allergy, cough and cold, dermatology, pain and cardiovascular risk prevention, and digestive health. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. The company has a collaboration with Acuitas Therapeutics, Inc. to strengthen gene editing programs; Peking University in the area of basic pharmaceutical research; the Swiss Tropical and Public Health Institute in the development of the compound emodepside for the treatment of infection with soil-transmitted helminths; bit.bio Ltd. for the discovery and manufacture of regulatory T cells for use in creating therapeutics; Hologic, Inc. in the field of contrastenhanced-mammography solutions to improve diagnostic imaging for the detection of breast cancer; and Twist Bioscience Corporation centering around the research and development of antibody-based pharmaceuticals, as well as with CrossBay Medical Inc. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company has collaboration with Thermo Fisher Scientific. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.

Bristol Myers Squibb NYSE:BMY

$46.76 +0.11 (+0.23%)

As of 12:00 PM Eastern

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

CSL OTCMKTS:CSLLY

$77.22 -2.19 (-2.76%)

As of 11:16 AM Eastern

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.

GSK NYSE:GSK

$38.74 +0.19 (+0.48%)

As of 11:59 AM Eastern

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time